Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0VL4V
|
||||
| Former ID |
DCL000233
|
||||
| Drug Name |
SR-123781A
|
||||
| Indication | Venous thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Phase 2/3 | [521845] | ||
| Company |
Sanofi-aventis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C91H137O111S17-19
|
||||
| Canonical SMILES |
COCC1C(C(C(C(O1)OC2C(OC(C(C2OC)OC)OC3C(OC(C(C3OC)OC)OC4<br />C(C(C(OC4C(=O)[O-])OC5C(OC(C(C5OS(=O)(=O)[O-])OS(=O)(=O<br />)[O-])OC6C(C(C(OC6C(=O)[O-])OC7C(OC(C(C7OC)OS(=O)(=O)[O<br />-])OC)COS(=O)(=O)[O-])OC)OC)COS(=O)(=O)[O-])OC)OC)COS(=<br />O)(=O)[O-])COC)OC)OC)OC8C(C(C(C(O8)COC)OC9C(C(C(C(O9)CO<br />S(=O)(=O)[O-])OC1C(C(C(C(O1)COS(=O)(=O)[O-])OC1C(C(C(C(<br />O1)CS(=O)(=O)[O-])OC1C(C(C(C(O1)COS(=O)(=O)[O-])OS(=O)(<br />=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])S(=O)(=O)[O-])S(=<br />O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OC)OC)OC)OC
|
||||
| InChI |
1S/C91H156O111S17/c1-147-20-30-40(182-82-66(159-13)52(152-6)42(32(174-82)22-149-3)184-84-68(161-15)54(154-8)44(35(176-84)25-168-208(111,112)113)187-88-73(200-217(138,139)140)61(197-214(129,130)131)47(37(178-88)27-170-210(117,118)119)189-91-77(205(102,103)104)76(204(99,100)101)49(39(181-91)29-203(96,97)98)190-89-75(202-219(144,145)146)62(198-215(132,133)134)48(195-212(123,124)125)38(180-89)28-171-211(120,121)122)50(150-4)65(158-12)81(173-30)183-41-31(21-148-2)175-83(67(160-14)51(41)151-5)185-43-34(24-167-207(108,109)110)177-85(69(162-16)53(43)153-7)191-58-56(156-10)71(164-18)87(194-63(58)78(92)93)188-46-36(26-169-209(114,115)116)179-90(74(201-218(141,142)143)60(46)196-213(126,127)128)192-59-57(157-11)70(163-17)86(193-64(59)79(94)95)186-45-33(23-166-206(105,106)107)172-80(165-19)72(55(45)155-9)199-216(135,136)137/h30-77,80-91H,20-29H2,1-19H3,(H,92,93)(H,94,95)(H,96,97,98)(H,99,100,101)(H,102,103,104)(H,105,106,107)(H,108,109,110)(H,111,112,113)(H,114,115,116)(H,117,118,119)(H,120,121,122)(H,123,124,125)(H,126,127,128)(H,129,130,131)(H,132,133,134)(H,135,136,137)(H,138,139,140)(H,141,142,143)(H,144,145,146)/p-19
|
||||
| InChIKey |
UGGUFTUNDZNVQR-UHFFFAOYSA-A
|
||||
| CAS Number |
CAS 232602-93-6
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Coagulation factor Xa | Target Info | Modulator | [535183] | |
| Coagulation factor IIa | Target Info | Modulator | [535183] | ||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Blood coagulationP00011:Blood coagulation | ||||
| Pathway Interaction Database | Beta2 integrin cell surface interactionsthrombin_pathway:Thrombin/protease-activated receptor (PAR) pathway | ||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| FOXA2 and FOXA3 transcription factor networks | |||||
| PAR4-mediated thrombin signaling events | |||||
| Syndecan-4-mediated signaling events | |||||
| PAR1-mediated thrombin signaling events | |||||
| PathWhiz Pathway | CoagulationPW000047:Vitamin K Metabolism | ||||
| Coagulation | |||||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | ||||
| Intrinsic Pathway of Fibrin Clot Formation | |||||
| Common Pathway of Fibrin Clot Formation | |||||
| Gamma-carboxylation of protein precursors | |||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteinsR-HSA-140837:Intrinsic Pathway of Fibrin Clot Formation | |||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||||
| Cell surface interactions at the vascular wall | |||||
| Peptide ligand-binding receptors | |||||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||||
| G alpha (q) signalling events | |||||
| Thrombin signalling through proteinase activated receptors (PARs) | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Human Complement System | |||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||||
| Blood Clotting Cascade | |||||
| Formation of Fibrin Clot (Clotting Cascade)WP558:Complement and Coagulation Cascades | |||||
| Regulation of Actin Cytoskeleton | |||||
| IL1 and megakaryotyces in obesity | |||||
| Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Thrombin signalling through proteinase activated receptors (PARs) | |||||
| Platelet Aggregation (Plug Formation) | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| Cell surface interactions at the vascular wall | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.